Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01954030 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure
A Phase 1 study, sponsored by Annick Desjardins.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT01954030 is a Phase 1 study that was terminated before completion, run by Annick Desjardins. The registered enrollment target is 17 participants.
The verdict
NCT01954030, a Phase 1 study, was terminated before completion, sponsored by Annick Desjardins.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The primary objectives of the study are to determine the maximum tolerated dose (MTD) of Carboxyamidotriazole Orotate (CTO) when combined with standard dosing of bevacizumab among patients with recurrent malignant glioma (WHO grade III or IV) that have previously failed bevacizumab (Phase 1); to determine the activity of CTO alone in bevacizumab-failure WHO grade IV malignant glioma patients (Phase 2, Arm 1); to determine the activity of CTO plus bevacizumab in bevacizumab-failure WHO grade IV malignant glioma patients (Phase 2, Arm 2). This study was terminated early due to funding issues. At the time of termination, the study was still in Phase 1 and no MTD for the combination of CTO and bevacizumab had been determined for this population. Phase 2 will not proceed.
Interventions
- DRUG CTO and Bevacizumab
- DRUG CTO alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01954030
The ClinicalTrials.gov registry entry for NCT01954030 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Annick Desjardins, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CTO and Bevacizumab is the first listed.
NCT01954030 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01954030 about?
NCT01954030 is a clinical study titled "Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure". The primary objectives of the study are to determine the maximum tolerated dose (MTD) of Carboxyamidotriazole Orotate (CTO) when combined with standard dosing of bevacizumab among patients with recurrent malignant glioma (WHO grade III or IV) that have previously failed bevacizumab (Phase 1); to det...
What is the current status of trial NCT01954030?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2013-10. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01954030?
The interventions under investigation include: CTO and Bevacizumab (DRUG), CTO alone (DRUG).
Who is sponsoring clinical trial NCT01954030?
This trial is sponsored by Annick Desjardins, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.